Clinical Trial Update: A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study of JNJ-63733657 in participants with early Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• JNJ-63733657

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Alzheimer Disease, Cognitive Dysfunction | Phase 2 | Status: TERMINATED